<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2015-0-2-3-76-83</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-72</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Изучение сократительной функции и степени повреждения миокарда на модели изолированного сердца крысы, подвергшегося четырехчасовой кардиоплегической ишемии и реперфузии в условиях посткондиционирования левосименданом</article-title><trans-title-group xml:lang="en"><trans-title>A study of myocardial contractile function and injury degree on a model of isolated rat heart subjected to four-hour car-dioplegic ischemia and reperfusion under conditions of postconditioning by levosimendan</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торопова</surname><given-names>Яна Геннадьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Toropova</surname><given-names>Yana G.</given-names></name></name-alternatives><email xlink:type="simple">yana.toropova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осяев</surname><given-names>Николай Юрьевич</given-names></name><name name-style="western" xml:lang="en"><surname>Osyaev</surname><given-names>Nikolay Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долинчик</surname><given-names>Татьяна Ринатовна</given-names></name><name name-style="western" xml:lang="en"><surname>Dolinchik</surname><given-names>Tatiana R.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотников</surname><given-names>Георгий Павлович</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikov</surname><given-names>Georgy P.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шукевич</surname><given-names>Дмитрий Леонидович</given-names></name><name name-style="western" xml:lang="en"><surname>Shukevich</surname><given-names>Dmitry L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Головкин</surname><given-names>Алексей Сергеевич</given-names></name><name name-style="western" xml:lang="en"><surname>Golovkin</surname><given-names>Alexey Sergeevich</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «НИИ Комплексных проблем сердечно-сосудистых заболеваний» Сибирского отделения РАМН<country>Россия</country></aff><aff xml:lang="en">Research Science Institute for Complex Issues of Cardiovascular Diseases of Siberian Branch of the Russian Academy of Medical Sciences<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">МБУЗ «Кемеровский кардиологический диспансер»<country>Россия</country></aff><aff xml:lang="en">Municipal State Budgetary Institution Kemerovo Cardiology Dispensary<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>2-3</issue><fpage>76</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Торопова Я.Г., Осяев Н.Ю., Долинчик Т.Р., Плотников Г.П., Шукевич Д.Л., Головкин А.С., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Торопова Я.Г., Осяев Н.Ю., Долинчик Т.Р., Плотников Г.П., Шукевич Д.Л., Головкин А.С.</copyright-holder><copyright-holder xml:lang="en">Toropova Y.G., Osyaev N.Y., Dolinchik T.R., Plotnikov G.P., Shukevich D.L., Golovkin A.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/72">https://transmed.almazovcentre.ru/jour/article/view/72</self-uri><abstract><p>Необходимость совершенствования методов защиты миокарда от ишемических и реперфузионных повреждений обусловлена широким внедрением в кардиологическую практику методов трансплантации сердца и увеличением числа оперативных вмешательств на сердце в условиях искусственного кровообращения. На модели изолированного сердца крысы, подвергшегося четырехчасовой фармакохолодовой кардиоплегии и реперфузии в условиях кардиопротекции левосименданом, изучались сократительная функция и степень повреждения миокарда. Установлено наличие кардиопротективного эффекта посткондиционирования левосименданом в отношении изолированного сердца в реперфузионном периоде четырехчасовой кардиоплегической ишемии. Данный эффект проявлялся в снижении реперфузионного выброса ферментов - маркеров повреждения миокарда и полном восстановлении параметров сократительной активности изолированных сердец в реперфузионном периоде.</p></abstract><trans-abstract xml:lang="en"><p>A widespread introduction of cardiac transplantation methods into cardiological practice and increase in a number of cardiopulmonary bypass surgical interferences determine the necessity of improvement of myocardial protection methods from ischemic and reperfusion injuries. Myocardial contractile function and injury degree were studied on a model of isolated rat heart subjected to four-hour pharmaco-hypothermic cardioplegia and reperfusion under conditions of cardioprotection by levosimendan. The presence of cardioprotective effect of postconditioning by levosimendan in regard to an isolated heart in reperfusion period of four-hour cardioplegic ischemia was found out. The given effect was manifested in reducing of reperfusion ejection of myocardial injury enzymatic markers and a complete restoration of contractive activity parameters of isolated hearts in reperfusion period.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>изолированное сердце</kwd><kwd>фармакохолодовая кардиоплегия</kwd><kwd>реперфузия</kwd><kwd>левосимендан</kwd><kwd>фармакологическое посткондиционирование</kwd><kwd>isolated heart</kwd><kwd>pharmaco-hypothermic cardioplegia</kwd><kwd>reperfusion</kwd><kwd>levosimendan</kwd><kwd>pharmacological postconditioning</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Писаренко ОИ, Шульженко ВС, Студнева ИМ. Улучшение восстановления функции изолированного сердца модифицированным реперфузионным раствором. Кардиология. 2005;45(7):38-43.</mixed-citation><mixed-citation xml:lang="en">Писаренко ОИ, Шульженко ВС, Студнева ИМ. Улучшение восстановления функции изолированного сердца модифицированным реперфузионным раствором. Кардиология. 2005;45(7):38-43.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Шляхто ЕВ, Галагудза ММ, Сыренский АВ. и др. Ишемическое посткондиционирование миокарда: новый способ защиты сердца от реперфузионного повреждения. Терапевтический архив. 2005;77(5):77-80.</mixed-citation><mixed-citation xml:lang="en">Шляхто ЕВ, Галагудза ММ, Сыренский АВ. и др. Ишемическое посткондиционирование миокарда: новый способ защиты сердца от реперфузионного повреждения. Терапевтический архив. 2005;77(5):77-80.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115 (14):1895-1903.</mixed-citation><mixed-citation xml:lang="en">Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115 (14):1895-1903.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Наумов АБ, Баутин АЕ, Кутин АМ и др. Применение левосимендана для лечения кардиогенного шока, связанного с развитием острой правожелудочковой недостаточности после аортокоронарного шунтирования. Кардиология и сердечно-сосудистая хирургия. 2009;49(1):79-81.</mixed-citation><mixed-citation xml:lang="en">Наумов АБ, Баутин АЕ, Кутин АМ и др. Применение левосимендана для лечения кардиогенного шока, связанного с развитием острой правожелудочковой недостаточности после аортокоронарного шунтирования. Кардиология и сердечно-сосудистая хирургия. 2009;49(1):79-81.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kolseth SM, Rolim NP, Salvesen O, Nordhaug DO, Wahba A, Hoydal MA. Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure. Acta Physiol (Oxf). 2014;210(4):865-874. doi: 10.1111/apha.12248.</mixed-citation><mixed-citation xml:lang="en">Kolseth SM, Rolim NP, Salvesen O, Nordhaug DO, Wahba A, Hoydal MA. Levosimendan improves contractility in vivo and in vitro in a rodent model of post-myocardial infarction heart failure. Acta Physiol (Oxf). 2014;210(4):865-874. doi: 10.1111/apha.12248.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lepran I, Pollesello P, Vajda S, Varró A, Papp JG. Preconditioning Effects of Levosimendan in a Rabbit Cardiac Ischemia-Reperfusion Model. J Cardiovasc Pharmacol. 2006;48 (4):148-152.</mixed-citation><mixed-citation xml:lang="en">Lepran I, Pollesello P, Vajda S, Varró A, Papp JG. Preconditioning Effects of Levosimendan in a Rabbit Cardiac Ischemia-Reperfusion Model. J Cardiovasc Pharmacol. 2006;48 (4):148-152.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol. 2010;105(2):155-167. doi: 10.1007/s00395-009-0064-9.</mixed-citation><mixed-citation xml:lang="en">Hönisch A, Theuring N, Ebner B, Wagner C, Strasser RH, Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol. 2010;105(2):155-167. doi: 10.1007/s00395-009-0064-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kaheinen P1, Pollesello P, Levijoki J, Haikala H. Levosim endan Increases Diastolic Coronary Flow in Isolated Guinea-Pig Heart by Opening ATP-Sensitive Potassium Channels. J Cardiovasc Pharmacol. 2001;37(4):367-74.</mixed-citation><mixed-citation xml:lang="en">Kaheinen P1, Pollesello P, Levijoki J, Haikala H. Levosim endan Increases Diastolic Coronary Flow in Isolated Guinea-Pig Heart by Opening ATP-Sensitive Potassium Channels. J Cardiovasc Pharmacol. 2001;37(4):367-74.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, Grossini E. Levosimendan Modulates Programmed Forms of Cell Death Through KATP Channels and Nitric Oxide. J Cardiovasc Pharmacol. 2011;57(2):246-258. doi:10.1097/ FJC.0b013e318204bb55.</mixed-citation><mixed-citation xml:lang="en">Uberti F, Caimmi PP, Molinari C, Mary D, Vacca G, Grossini E. Levosimendan Modulates Programmed Forms of Cell Death Through KATP Channels and Nitric Oxide. J Cardiovasc Pharmacol. 2011;57(2):246-258. doi:10.1097/ FJC.0b013e318204bb55.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Минасян СМ, Галагудза ММ, Дмитриев ЮВ и др. Консервация донорского сердца: история и современность с позиции трансляционной медицины. Регионарное кровообращение и микроциркуляция. 2014;13(3):4-16.</mixed-citation><mixed-citation xml:lang="en">Минасян СМ, Галагудза ММ, Дмитриев ЮВ и др. Консервация донорского сердца: история и современность с позиции трансляционной медицины. Регионарное кровообращение и микроциркуляция. 2014;13(3):4-16.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Минасян СМ, Галагудза ММ, Сонин ДЛ и др. Методика перфузии изолированного сердца крысы. Регионарное кровообращение и микроциркуляция. 2010;8(4):54-59.</mixed-citation><mixed-citation xml:lang="en">Минасян СМ, Галагудза ММ, Сонин ДЛ и др. Методика перфузии изолированного сердца крысы. Регионарное кровообращение и микроциркуляция. 2010;8(4):54-59.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sutherland FJ, Shattock MJ, Baker KE, Hearse DJ. Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol. 2003;30(11):867-878.</mixed-citation><mixed-citation xml:lang="en">Sutherland FJ, Shattock MJ, Baker KE, Hearse DJ. Mouse isolated perfused heart: characteristics and cautions. Clin Exp Pharmacol Physiol. 2003;30(11):867-878.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ozturk T, Gok S, Nese N. Levosimendan attenuates reperfusion injury in an isolated perfused rat heart model. J Cardiothorac Vasc Anesth. 2010;24(4):624-628. doi: 10.1053/j. jvca.2009.08.003.</mixed-citation><mixed-citation xml:lang="en">Ozturk T, Gok S, Nese N. Levosimendan attenuates reperfusion injury in an isolated perfused rat heart model. J Cardiothorac Vasc Anesth. 2010;24(4):624-628. doi: 10.1053/j. jvca.2009.08.003.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K (ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154(1):41-50. doi: 10.1038/bjp.2008.52.</mixed-citation><mixed-citation xml:lang="en">du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and K (ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154(1):41-50. doi: 10.1038/bjp.2008.52.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Галагудза ММ. Оглушенный (станнированный) миокард: механизмы и клиническая значимость. Бюллетень ФЦСКЭ им. В. А. Алмазова. 2011;2:5-11.</mixed-citation><mixed-citation xml:lang="en">Галагудза ММ. Оглушенный (станнированный) миокард: механизмы и клиническая значимость. Бюллетень ФЦСКЭ им. В. А. Алмазова. 2011;2:5-11.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Marban E. Patogenetic role for calcium in stunning? Cardiovasc Drugs Ther. 1991;5(5):891-893.</mixed-citation><mixed-citation xml:lang="en">Marban E. Patogenetic role for calcium in stunning? Cardiovasc Drugs Ther. 1991;5(5):891-893.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sekili S, McCay PB, Li XY et al. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial “stunning” in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effect. Circ Res. 1993;73(4):705-723.</mixed-citation><mixed-citation xml:lang="en">Sekili S, McCay PB, Li XY et al. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial “stunning” in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effect. Circ Res. 1993;73(4):705-723.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Papp Z, Édes I, Fruhwald S, De Hert SG et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82-87. doi: 10.1016/j.ijcard.2011.07.022.</mixed-citation><mixed-citation xml:lang="en">Papp Z, Édes I, Fruhwald S, De Hert SG et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82-87. doi: 10.1016/j.ijcard.2011.07.022.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Papp Z, Csapó K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23(1):71-98.</mixed-citation><mixed-citation xml:lang="en">Papp Z, Csapó K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev. 2005;23(1):71-98.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
